lutetium (177Lu) vipivotide tetraxetan
GPTKB entity
Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
radiopharmaceutical |
| gptkbp:activeIngredient |
lutetium-177
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
V10XX05
|
| gptkbp:brand |
gptkb:Pluvicto
|
| gptkbp:CASNumber |
2451486-26-1
|
| gptkbp:chemicalFormula |
C49H72LuN14O14
|
| gptkbp:developer |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
lutetium (177Lu) vipivotide tetraxetan
|
| gptkbp:indication |
metastatic castration-resistant prostate cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
targets PSMA-expressing cells
|
| gptkbp:radioisotope |
lutetium-177
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever nausea vomiting diarrhea edema abdominal pain constipation dizziness fatigue hypertension urinary tract infection back pain weight loss cough hematuria thrombocytopenia dry mouth dyspnea decreased appetite musculoskeletal pain increased creatinine decreased hemoglobin decreased platelet count decreased lymphocytes decreased neutrophil count decreased white blood cell count |
| gptkbp:target |
prostate-specific membrane antigen
|
| gptkbp:UNII |
6Q1K1Q1K1K
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:Pluvicto
|
| gptkbp:bfsLayer |
6
|